## First-Line Treatment of Uncomplicated P. falciparum Malaria **Key Point:** Artemisinin-based combination therapy (ACT) is the WHO-recommended and Indian national guideline first-line treatment for uncomplicated P. falciparum malaria worldwide, including India. ### Why ACT is Correct **High-Yield:** ACTs combine a fast-acting artemisinin derivative with a longer-acting partner drug: - Artemisinin derivatives (artemether, artesunate, artemether) kill parasites rapidly within 3 days - Partner drugs (lumefantrine, amodiaquine, piperaquine) eliminate remaining parasites and prevent recrudescence - Synergistic action reduces treatment duration to 3 days - Delays resistance development through dual mechanism ### Recommended ACT Regimens in India | ACT Combination | Artemisinin Component | Partner Drug | Duration | | --- | --- | --- | --- | | Artemether-lumefantrine | Artemether | Lumefantrine | 3 days | | Artesunate-amodiaquine | Artesunate | Amodiaquine | 3 days | | Dihydroartemisinin-piperaquine | Dihydroartemisinin | Piperaquine | 3 days | **Clinical Pearl:** ACTs achieve >95% cure rates in uncomplicated malaria and are safe in pregnancy (after first trimester). They are the standard of care globally and per Indian National Vector Borne Disease Control Programme (NVBDCP) guidelines. **Mnemonic:** **ACT Fast** — Artemisinin-based Combination Therapy works Fast (3-day cure). ### Why Chloroquine is No Longer Used - P. falciparum developed widespread chloroquine resistance by the 1980s–1990s - Chloroquine monotherapy now has <50% efficacy in most endemic regions - Causes treatment failure and selection of resistant strains **Warning:** Chloroquine is NOT used for P. falciparum; it is reserved only for P. malariae and P. ovale (where resistance is rare).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.